The Role of Monoclonal Antibodies in Preventing Infections

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

monoclonal antibody treatment could be going forward. We know that they're not necessarily very effective once someone has severe disease. But given that we know that monocloneati bodies do seem to be quite effective at early stages of infection, they could work as a post exposure prophylactic. Abi there is the point that it's going to take us a while to vaccinate everybody. If we have a way to help prevent serious illness in people prior to their being vaccinated, then that's useful.

In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.

But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.

News: COVID antibody treatments show promise for preventing severe disease

News: Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.